Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Table 4 Evolution of gastrointestinal toxicity, anticipatory/associative intolerance and behavioral symptoms

Months	n^a	MISS O	MTX intolerance	Anticipatory and/or associative symptoms	Gastrointestinal toxicity	Behavioral symptoms
		n (%)	n (%)	n (%)	n (%)	n (%)
3	53	19(3.8 %)	10 (18.5 %)	11 (20.8 %)	16 (30.2 %)	31 (58.5 %)
6	54	13 (24.1 %)	14 (25.5 %)	16 (29.6 %)	25 (46.3 %)	33 (66.1 %)
9	49	17 (34.7 %)	14 (28.0 %)	13 (26.5 %)	20 (40.8 %)	27 (55.1 %)
12	49	18 (36.7 %)	15 (30.6 %)	9 (18.4 %)	16 (32.7 %)	28 (57.1 %)

MISS, Methotrexate Intolerance Severity Score
^aMISS not available for 2 patients at Month 3. In subsequent months numbers reduced by patients who withdrew (n = 5), in 1 patient MISS at 9 and 12 months not available

ISSN: 1546-0096